Form 4: Heron Therapeutics CEO Craig Collard Reports Stock Transactions
SEC Form 4 Filing
CEO Craig Collard reported the vesting of restricted stock units and subsequent acquisition of common stock.
Summary
- On October 19, 2024, Craig Collard, CEO of Heron Therapeutics, reported transactions involving restricted stock units and common stock.
- 13,797 restricted stock units vested and were converted into 13,797 shares of common stock.
- Following the transaction, Collard directly owns 290,387 shares of common stock and 179,359 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common for executives who receive stock-based compensation. It provides transparency into the holdings of company leadership.
Key Dates
| Date | Description |
|---|---|
| 01/19/2024 | Date of grant for restricted stock units, which vest in 16 equal quarterly installments beginning one quarter after this date. |
| 10/19/2024 | Date of transaction: vesting of restricted stock units and acquisition of common stock. |
| 10/21/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.